See our range of cfDNA products below.
Ensuring successful cfDNA analysis is our focus
Every sample is precious and to get the most out of your sample when evaluating cfDNA it is really critical to have processed your samples correctly from blood collection through to extracted cfDNA. Learn more about our Cell3™ Preserver blood tube and Cell3™ Xtract kit below.
Non-invasive prenatal testing requires sensitive, reproducible and easy to use products.
Nonacus continues to develop innovative products to meet these exacting standards including tests for fetal rhesus-D genotyping, fetal fraction quantitation and single gene disorder testing.
Efficient workflow enables confident calling of all ctDNA mutations
Nonacus are working with some of the brightest scientists and clinicians by providing a validated complete workflow for liquid biopsy analysis. With the ultimate goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.
Who we are
Designed by scientists, for Scientists
We are formed of a committed group of biotechnology professionals with a combined 35 years experience in genomic healthcare. We understand the pressure on laboratories to deliver progress and our products are designed to get you there. Between us, we’ve got global experience of genomic healthcare from the NHS in the UK through to an international genome project.
What we stand for
True Innovation That Benefits Patients
We translate research into routine diagnostic tools that directly benefit patients and scientists. Our non-invasive cell free DNA solutions improve diagnostic accuracy as well as the patient’s experience. Our research & development team are constantly developing, validating and testing new cfDNA products.
Built For Labs That Do
We supply Universities with our cfDNA products to help them improve their understanding and research in non-invasive healthcare.
Leading hospitals have adopted our products to help improve patient care through the innovative use of cfDNA technology allowing for non-invasive diagnostics.
We partner with many leading laboratories to constantly innovate and push our products further.
Read Our Latest Insights
Despite causing similar symptoms, there are key differences between COVID-19, flu and RSV such as the size and structure of the viral genome as well as the virion proteins. These differences allow us to design tests to distinguish between these viral infections and develop treatments and vaccines specific to each.Read More
Cell3™ Target becomes the first pan-cancer NGS panel for liquid biopsy profiling of childhood cancer
A group at the Institute of Cancer Research recently published the validation of a Nonacus pan-cancer sequencing panel for liquid biopsy molecular diagnostics which could be used to profile tumor DNA in the blood of paediatric cancer patients. This opens up the possibility to routinely sample patients, monitoring their response to treatment and following their disease progression, to detect relapse as early as possible.Read More
Last July we announced that Nonacus and the University of Birmingham had partnered to develop a non-invasive test for bladder cancer. The test uses highly sensitive liquid biopsy technology developed by Nonacus, and a panel of biomarkers validated by Dr Rik Bryan and Dr Douglas Ward from the University’s Bladder Cancer Research Centre, to diagnose the disease from urine samples. Now, less that a year later, the first results are in.Read More